Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 5
2019 2
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.
Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, Buckner JC, Elmquist WF. Sarkaria JN, et al. Among authors: laramy jk. Neuro Oncol. 2018 Jan 22;20(2):184-191. doi: 10.1093/neuonc/nox175. Neuro Oncol. 2018. PMID: 29016900 Free PMC article. Review.
Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma.
Randall EC, Emdal KB, Laramy JK, Kim M, Roos A, Calligaris D, Regan MS, Gupta SK, Mladek AC, Carlson BL, Johnson AJ, Lu FK, Xie XS, Joughin BA, Reddy RJ, Peng S, Abdelmoula WM, Jackson PR, Kolluri A, Kellersberger KA, Agar JN, Lauffenburger DA, Swanson KR, Tran NL, Elmquist WF, White FM, Sarkaria JN, Agar NYR. Randall EC, et al. Among authors: laramy jk. Nat Commun. 2018 Nov 21;9(1):4904. doi: 10.1038/s41467-018-07334-3. Nat Commun. 2018. PMID: 30464169 Free PMC article.
Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma.
Laramy JK, Kim M, Gupta SK, Parrish KE, Zhang S, Bakken KK, Carlson BL, Mladek AC, Ma DJ, Sarkaria JN, Elmquist WF. Laramy JK, et al. J Pharmacol Exp Ther. 2017 Nov;363(2):136-147. doi: 10.1124/jpet.117.243477. Epub 2017 Aug 28. J Pharmacol Exp Ther. 2017. PMID: 28847917 Free PMC article.
In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling.
Kizilbash SH, Gupta SK, Parrish KE, Laramy JK, Kim M, Gampa G, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Elmquist WF, Sarkaria JN. Kizilbash SH, et al. Among authors: laramy jk. Mol Cancer Ther. 2021 Jun;20(6):1009-1018. doi: 10.1158/1535-7163.MCT-20-0640. Epub 2021 Mar 30. Mol Cancer Ther. 2021. PMID: 33785646